HOME >> MEDICINE >> NEWS
Anaesthetists need urgent guidance on patients who don't want to be resuscitated

UK anaesthetists could face accusations of euthanasia or assisted suicide if they follow Do Not Attempt Resuscitation (DNAR) Orders during surgery, according to an editorial in the July issue of Anaesthesia.

Patients who have surgery often need routine interventions during anaesthesia that could be classed as resuscitation, points out Consultant Anaesthetist Dr Michael McBrien from the Royal Victoria Hospital in Belfast, Northern Ireland.

But automatically suspending DNAR Orders during surgery is no longer an acceptable option, according to Dr McBrien and his editorial co-author, Dr Gary Heyburn, Associate Specialist Orthogeriatrician at the Hospital.

"If the anaesthetist were to proceed and strictly obey the general understanding of a DNAR order under such circumstances, it could possibly be construed as an act of euthanasia or assisted suicide" they stress.

McBrien and Heyburn say that UK clinicians urgently need national guidance on how to manage the growing number of DNAR orders, pointing out that American guidelines have been in place since 1993.

"It is surprising that no guidelines or serious discussions on this matter have appeared in the UK to parallel the developments in North America" adds Dr McBrien.

The need for guidelines has been given added impetus by the fact that the Mental Capacity Act is due to come into force next year and that the European Convention on Human Rights is now enshrined in UK Law.

From 1 April 2007, the Act will give formal legal recognition to the patient's right to make advance decisions about the care they receive and reinforce the common law position about DNAR Orders that already exists.

"The paternalistic primary ethical principal of the past, namely immediate medical benefit to the patient, has been overtaken" says Dr McBrien.

"If we are not to face litigation in the future we must read, understand and implement what the law requires from
'"/>

Contact: Annette Whibley
wordwizard@clara.co.uk
Blackwell Publishing Ltd.
28-Jun-2006


Page: 1 2

Related medicine news :

1. Experts call for urgent research into anti-epileptic drugs given to children
2. Disadvantaged TB patients urgently need social support to make medical treatment more effective
3. Humanitarian response urgently needed to address Lebanese health crisis
4. World Hypertension League calls for urgent action to get more hypertensive patients to goal
5. Doctors call for urgent review of cancer initiative
6. UK liver services need urgent improvement
7. National Service Framework for heart failure urgently needed
8. Research urgently needed to treat blood clots in children
9. Urgent need for guidance on mobile phone use in clinical care
10. Menopausal women dont get enough guidance on treatment options, Stanford survey shows
11. The ESC releases guidance document on Cardiac Rhythm Management product performance

Post Your Comments:
(Date:4/22/2014)... percent of all lung cancers are small cell ... develop resistance to chemotherapy. However, researchers at Virginia ... insights into the mechanisms leading to this resistance ... Chemotherapies work primarily by mediating B-cell lymphoma 2 ... cell death. Depending on their function, this family ...
(Date:4/22/2014)... 2014Hemoglobin A1c is the standard measurement for assessing glycemic ... of A1c are typically measured every few months in ... model that accurately estimates A1c using self-monitored blood glucose ... Therapeutics ( DTT ), a peer-reviewed journal from ... free on the DTT website at ...
(Date:4/22/2014)... PHILADELPHIA (April 22, 2014) That person we all seem ... take action? Turns out he or she isn,t unable to ... A study of nearly ... about why neurotic people may avoid making decisions and moving ... if action is positive, favorable, good, they just don,t like ...
(Date:4/22/2014)... -- In parallel with modern man ( Homo sapiens ), ... we lived side by side, such as Neanderthals and the ... sapiens survived. What was it in our genetic makeup ... little is known about our unique genetic makeup as distinguished ... fact that we are the only species among them ,to ...
(Date:4/22/2014)... Disease (IBD), a group of chronic inflammatory disorders of ... affects over 1.4 million people in the U.S., and ... there is no cure. , Now, Cincinnati Cancer ... Susan Waltz, PhD, and scientists in her lab have ... genetic study to document the important function for the ...
Breaking Medicine News(10 mins):Health News:Scientists pinpoint protein that could improve small cell lung cancer therapies 2Health News:Neurotics don't just avoid action: They dislike it 2Health News:What gave us the advantage over extinct types of humans? 2Health News:Two genes linked to inflammatory bowel disease 2
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: PharmaPoint: Atopic ... Analysis to 2022 http://www.reportlinker.com/p01957657/PharmaPoint-Atopic-Dermatitis---India-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... India Drug Forecast and Market Analysis to ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a leading ... of severely obese patients, today announced initial results ... selective inhibitor of methionine aminopeptidase 2 (MetAP2), in ... of genetic obesity.  These results showed improvements in ...
(Date:1/14/2014)... , Jan. 14, 2014 InformEx, North America,s ... of high-value chemistry, will hold the 30 th edition ... Convention Center from January 21-24. (Logo: ... from top pharmaceutical, fine chemical and specialty chemical companies will ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
Cached News: